Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Cases of norovirus are on the rise just in time for the holiday season - 2Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- 3Launch pad damaged as Russian rocket blasts off for space station, agency says
- 4Prehistoric wolf’s gut frozen in time reveals an ice age giant
- 5Which game do you cherish observing live? Vote!
- Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- UPM Adhesive Materials plans new facility near New Delhi, India
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
- The Force of Positive Reasoning: Day to day Attestations
- How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- Trial of pro-Palestine activist begins
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Bad flu season getting worse; skyrocketing cases set state record
